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Abstract
Background: Many publications link high homocysteine levels to cardiovascular disease. In Spain there is
little information on the prevalence of hyperhomocysteinaemia and associated vitamin factors among the
general population, and less still among children. Cardiovascular risk factors in the childhood population
may be related to the appearance of cardiovascular disease at adult age. The aim of this study is to establish
a definition of hyperhomocysteinaemia in adolescents and to analyze the influence of vitamin and metabolic
factors in homocysteine levels in this population group.
Methods: Descriptive, cross-sectional epidemiological study to estimate serum homocysteine, vitamin
B12 and folate levels, as well as plasma total, HDL- and LDL- cholesterol in a schoolgoing population aged
13 to 17 years in Madrid, Spain.
Spearman correlation analysis was performed to ascertain quantitative comparison, Pearson's χ2 test
(frequency < 5, Fisher) was used for comparison of prevalences, Mann-Whitney U and Kruskal-Wallis test
were used for comparison of means and Bonferroni correction was used for post-hoc tests. A multivariate
logistic regression model was performed in the multivariate analysis.
Results: Based on the classic values for definition of hyperhomocysteinaemia in adults, prevalence of
hyperhomocysteinaemia in the study population was: 1.26% for 15 μmol/L; and 2.52% for 12 μmol/L.
Deficits in HDL cholesterol and serum folate levels yielded adjusted Odds Ratios (OR) for
hyperhomocysteinemia of 2.786, 95% CI (1.089-7.126), and 5.140, 95% CI (2.347-11.256) respectively.
Mutation of the methylenetetrahydrofolate reductase (MTHFR) C677T genotype also raises the risk of
hyperhomocysteinaemia (CC→CT: OR = 2.362; 95% CI (1.107-5.042) CC→TT: OR = 6.124, 95% CI
(2.301-16.303))
Conclusion: A good definition of hyperhomocysteinaemia in adolescents is the 90th percentile, equivalent
to 8.23 μmol/L. Risk factors for hyperhomocysteinaemia are cHDL and folate deficiency, and the MTHFR
C677T mutant genotype. No significant effect could be assessed for vitamin B12. Coexistence of all three
factors increases the risk of suffering from hyperhomocysteinaemia 87-fold.
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Background
In addition to being the principal cause of premature
death in most European countries, cardiovascular diseases
(CVDs) are a major cause of disability, and, by extension,
increased health care cost [1]. Such diseases are generally
due to a combination of several risk factors [2]. In 1996,
the 27th Bethesda Conference proposed hyperhomocystei-
naemia as one of the new cardiovascular risk factors [3,4].
Inasmuch as it involves a potentially modifiable and cor-
rectable risk factor, this hypothesis is of great health care
importance since it opens the door to a new form of inter-
vention against cardiovascular diseases, such as dietary
supplementation with group B vitamins and folic acid.
Homocysteine is a sulphur-containing amino acid derived
from methionine, present in proteins of animal origin
ingested as part of dietary intake. It is produced by intrac-
ellular demethylation of methionine and then exported to
the plasma, where it circulates, mainly in its oxidised
form.
Homocysteine is metabolised to methionine via remeth-
ylation or to cysteine via transulphuration at the hepatic
level. During vitamin B6-dependent transulphuration,
homocysteine is irreversibly catabolised into cysteine,
thanks to the action of cystathionine-β-synthetase
enzyme, in the presence of serine. Most of the homo-
cysteine is remethylated, regenerating methionine, mainly
due to the action of methionine synthetase, the enzyme
that depends on the action of methylcobalamine (vitamin
B12) as a co-factor and folate, in the form of 5-methyl-tet-
rahydrofolate, as a methyl group donor.
The enzyme, 5,10-methyl-tetrahydrofolate reductase
(MTHFR) reduces 5,10-methylenetetrahydrofolate to 5-
methyl-tetrahydrofolate in the presence of NADPH. This
reaction is irreversible in vivo and its activity regulates the
entry of folate into the homocysteine remethylation path-
way.
The MTHFR C677T mutation is the most frequent cause of
moderate hyperhomocysteinaemia due to genetic factors.
The TT genotype has been found to have a direct effect on
homocysteine concentration, with MTHFR enzymatic
activity being reduced by as much as 50% in individuals
with this mutation [5]. This polymorphism is present in
its homozygous form in 5%-18% of the population [6].
The effect of the TT homozygote genotype on homo-
cysteine concentration is not observed, however, when
folic acid levels are elevated [7]. This is due to the fact that,
despite the reduction in its enzymatic activity, MTHFR has
sufficient 5-10 methyltetrahydrofolate substrate to gener-
ate the 5-methyltetrahydrofolate necessary for remethyla-
tion of homocysteine.
When these reactions are altered, homocysteine accumu-
lates and is excreted into the blood, causing hyperhomo-
cysteinaemia [8], which, according to a number of
epidemiological studies, is associated with an increase in
the probability of suffering from CVDs [9-15].
Hyperhomocysteinaemia is defined as elevated concentra-
tion of fasting plasma total homocysteine.
As is the case with other parameters, such as arterial hyper-
tension, no threshold plasma homocysteine value has
been established, above which the risk of suffering from a
vascular disease is increased [16,17]. In most studies, this
threshold is obtained arbitrarily, with values above the
mean found in the control group plus two standard devi-
ations [17-20], or above the 95th percentile, being used to
define hyperhomocysteinaemia [16,17,20-22].
In Spain, Pijoan et al. constructed a reference interval (5-
15 μmol/l) based on a sample of 396 apparently healthy
individuals [23].
Plasma homocysteine levels increase with weight, height,
body mass index, blood pressure, systolic and diastolic
pressure, age, male gender and MHTFR 677TT genotype.
In contrast, they decrease with high plasma folate and
intraerythrocyte, vitamin B6 and vitamin B12 concentra-
tions.
The established drug treatments for hyperhomocysteinae-
mia are vitamin supplements consisting of folate, vitamin
B6, vitamin B12 or any combination of the three [24].
In the healthy paediatric population, homocysteine levels
are influenced more by biochemical than by genetic fac-
tors, due to the high folate reserves present during child-
hood. No significant differences in homocysteine levels
were observed between boys and girls until postpubertal
age, when these rise in males [25].
Arterosclerosis begins at early ages of life [26,27] and envi-
ronmental factors in childhood are known to be linked to
the appearance of cardiovascular disease at adult age [28].
Determination of plasma homocysteine in children could
have a predictive value vis-à-vis adult vascular risk [29].
Methods
A descriptive, cross-sectional epidemiological study was
conducted to estimate serum homocysteine levels in the
schoolgoing population aged 13 to 17 years in the Madrid
Region (Comunidad de Madrid). All children who partici-
pated (172 girls and 145 boys) were recruited at selected
junior schools, using random, stratified, cluster sampling.
Junior schools were selected in strata that would ensure
representation of socio-economic differences.Nutrition & Metabolism 2009, 6:39 http://www.nutritionandmetabolism.com/content/6/1/39
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For a level of precision of 3%, an estimated prevalence of
5% and a confidence level of 95%, a minimum sample
size of 202 was needed. Assuming lost of 20%, a total of
243 subjects was needed. (EPI-INFO 2002; version 6).
The study included subjects of both sexes, who were aged
over 13 years, attended schools in the Madrid Region and
produced informed consent. The following were subjects
excluded from the study: those whose parents failed to
sign the authorisation to participate; those who were
authorised but were nevertheless unwilling to participate;
and those who presented with some type of acute or
chronic illness that might affect the variables of interest.
In each case, data were collected on age, gender, physical
activity, blood pressure and anthropometric variables.
Anthropometric variables
Subjects' weight and height, as well as arm, waist and hip
circumferences were measured in duplicate, using cali-
brated precision scales (Seca 812, precision 0.1 kg), port-
able wall-mounted stadiometres (Seca Ka We 4444
model) and flexible, inelastic, plastic belt-type measuring
tapes fitted with a read-out buckle at one end. Body mass
index (weight in kg/height2 in m2) was then calculated on
the basis of these measures.
Blood pressure
Three readings were taken from each subject in accord-
ance with standardised guidelines issued by international
bodies, using a mercury sphygmomanometer (Diplomat
Presameter Riester Model) and an appropriately sized cuff
chosen in line with the individual's arm circumference.
Lipid profile
Cholesterol and triglyceride levels were measured in total
plasma through enzymatic methods.
In the case of girls, information was collected on the
appearance or non-appearance of menarchy.
Processing of blood specimens
A first morning, 12-hour, fasting, 14-ml blood specimen
was extracted from each subject by venipuncture, using a
Vacutainer tube containing EDTA-Na2 as antioxidant and
anticoagulant (10 ml EDTA) and an SST Vacutainer with-
out anticoagulant (4 ml SST).
The specimens were then stored on ice and sent immedi-
ately to the laboratory for analysis, where they were cen-
trifuged at 3500 rpm for 6 minutes a 4°C within the hour.
Determination of total homocysteine
Total homocysteine in the fasting blood specimen [30]
was determined, using an Abbott Diagnostics fluores-
cence polarisation immunoassay (FPIA). For multivariate
analysis, higher decile (P90) was defined as hyperhomo-
cysteinemia.
Determination of vitamin B12
Vitamin B12 (Vit B12) in the fasting blood specimen [31]
was determined, using a Roche Elecsys E170 MODULAR
ANALYTICS immunoanalysis assay.
Determination of folate
Folate in the fasting blood specimen [32] was determined,
using a Roche Elecsys E170 MODULAR ANALYTICS
immunoanalysis assay.
Determination of the MTHFR C677T genotype
Replacement of cytosine by thimine at nucleotide posi-
tion 677 converts the amino acid, alanine, into valine:
(normal genotype = CC, heterozygous genotype = CT,
mutated homozygous genotype = TT). DNA was ampli-
fied by PCR in a PTC-100 thermal cycler using nucle-
otides:
Forward: 5'TGAAGGAGAAGGTGTCTGCGGGA 3'
Reverse: 3'AGGACGGTGCGGTGAGGAGGTG 3'.
The product of this reaction was digested with HinfI
restriction enzyme, and the fragments then separated in
non-denaturing polyacrylamide gel.
For a negative control, distilled water instead of DNA in
the reaction system was used for each panel of PCR. For
positive DNA control, DyNAzyme DNA Polymerase Kit
(Finnzymes Oy) was used.
Statistical data analysis
Based on all the valid data obtained, we performed a
descriptive analysis of both the independent and depend-
ent variables of interest, using centralisation and disper-
sion measures (means or medians where the distribution
was asymmetric), accompanied by their corresponding
95% confidence intervals in the case of quantitative varia-
bles and distribution of frequencies (prevalences and pro-
portions with 95% confidence intervals) in the case of
qualitative variables.
This analysis was stratified by gender, presence of men-
struation, age group, and MTHFR C677T genotype.
The normality of the homocedasticity variables was veri-
fied using the Kolmogorov-Smirnov test. Where variables
did not follow a normal distribution, non-parametric tests
were used. Homoscedasticity or homogeneity of variances
was examined using Levene's test.
A Spearman correlation analysis was performed to ascer-
tain the magnitude of the linear relationship between theNutrition & Metabolism 2009, 6:39 http://www.nutritionandmetabolism.com/content/6/1/39
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quantitative anthropometric, biochemical and metabolic
cycle variables and homocysteine values. The technique
used for comparison of prevalences was Pearson's χ2 test
(frequency < 5, Fisher). We used the Mann-Whitney U test
for comparison of means, and the Kruskal-Wallis test for
variables with more than two categories or for inclusion of
different variables simultaneously. Bonferroni correction
was used for post-hoc tests to ensure that all comparisons
were made with α = 0.05.
Independent variables that displayed a significant associ-
ation in the simple analysis as well as those that were clin-
ically linked to the study variable, were included in a
multivariate logistic regression model. Based on this, the
adjusted Odds Ratios of the principal study factors were
obtained, along with their corresponding 95% confidence
intervals.
In all hypothesis testing to determine differences, associa-
tions and relationships were deemed significant at p <
0.05.
Statistical data analyses were performed using the SPSS
computer software programme (Statistical Package for
Social Sciences) version 16.0.
Ethical aspects
The research protocol was approved by the Jiménez Díaz
Foundation Clinical Research Ethics Committee. This
study complied in all respects with the ethical safeguards
laid down by the Helsinki Declaration and its subsequent
updates, and with Spanish legislation governing clinical
research involving humans and protection of data of a
personal nature
Results
The study population totalled 317 students, 50% aged 13
years, 35% aged 14 years and 15% aged 15 or more years;
54% were females and 46% males. The mean age of the
study subjects was 13.69 years, 95% CI (13.60-13.78),
and their anthropometric characteristics corresponded to
the expected values for their age.
Table 1 shows the serum or plasma values for the princi-
pal biochemical variables and possible hormonal factors
implicated in cardiovascular disease. Mean concentra-
tions were as follows: serum folate, 7.83 nM, 95% CI
(7.42-8.23) nM; vitamin B12, 503 pM, 95% CI (478-528)
pM; and homocysteine, 4.92 μM, 95% CI (4.50-5.35) μM.
Taking the classic values as reference, prevalence of hyper-
homocysteinaemia in the study population was 1.26% for
15 μmol/L, and 2.52% for 12 μmol/L. Table 2 defines dif-
ferent cut-off points for hyperhomocysteinaemia in chil-
dren.
When analysing MTHFR C677T genotype, normal
homozygous CC in the methylenetetrahydrofolate reduct-
ase enzyme was present in 37.8%, heterozygous CT geno-
type was present in 47.3%, and TT genotype,
corresponding to the homozygous mutation, was present
in 14.9% of cases.
Table 3 shows the prevalence of potential cardiovascular
risk factors and variables implicated in homocysteine
metabolism. Of the total study population, 23.8% dis-
played deficient serum folate levels (≤ 5.3 nmol/l) and
24.6% displayed deficient vitamin B12 levels (≤ 336 pmol/
l). Overweight, elevated glucose levels, deficient vitamin
B12  and HDL cholesterol values were greater in boys,
whilst girls showed greater sedentariness and hypercho-
lesterolaemia. Prevalence of occasional tobacco and alco-
hol use increased with age. Folate deficit was significantly
greater among subjects that displayed total (homozygote
TT) mutation of the MTHFR C677T genotype (Table 3).
In order to assess analyze the influence of vitamin and
metabolic factors in homocysteine levels in this popula-
tion group, hyperhomocysteinemia was defined as per-
centile 90th. Crude analysis showed how prevalence of
hyperhomocysteinaemia increases with male gender
(32.4% vs. 18.0% in female), age (21.0%, 22.3%, 40.4%
for 13, 14 and >14, respectively), mutation of the MTHFR
C677T genotype (15.1%, 24.8%, 46.8% for CC, CT and
TT genotype, respectively), HDL cholesterol (22,7% vs.
37.2% for normal and low levels, respectively) and defi-
cient folate values (19.4 vs. 43.2% for normal and low lev-
els, respectively). These independent variables, as well of
other of interest as vitamin B12, were included in a multi-
variate logistic regression model, obtaining adjusted Odds
Ratios for the principal study factors (Table 4).
Deficient HDL cholesterol and serum folate levels regis-
tered adjusted Odds Ratios of OR = 2.786, 95% CI (1.089-
Table 1: Biochemical variables and hormonal factors
Mean 95% Confidence Interval
Glucose (mg/dl) 90.9 90.0-91.9
Total cholesterol (mg/dl) 160.9 157.9-163.9
HDL cholesterol (mg/dl) 47.3 46.0-48.7
LDL cholesterol(mg/dl) 96.7 94.0-99.4
Total cholesterol/cHDL 3.60 3.48-3.71
cLDL/cHDL 2.20 2.10-2.30
Menarche age (years) 12.01 11.86-12.15
Folate (nmol/L) 7.83 7.42-8.23
Vitamin B12 (pmol/L) 503 478-528
Homocysteine (μmol/L) 4.92 4.50-5.35
HDL: High Density Lipoproteins
LDL: Low Density LipoproteinsNutrition & Metabolism 2009, 6:39 http://www.nutritionandmetabolism.com/content/6/1/39
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7.126) and OR = 5.140, 95% CI (2.347-11.256) respec-
tively. The MTHFR C677T mutant genotype raised the risk
of hyperhomocysteinaemia (CC→CT: OR = 2.362; 95%
CI (1.107-5.042) CC→TT: OR = 6.124, 95% CI (2.301-
16.303))
After plausible biologically interactions have been ruled
out, the multiplicative nature of the association among
several risk factors in the sample can be observed, namely,
prevalence of hyperhomocysteinaemia increases in
accordance with the number of risk factors (FR) that accu-
mulate.
From Table 5, it will be seen how the prevalence of hyper-
homocysteinaemia rises when deficient folate and HDL
cholesterol values and mutant genotype coincide. Shown
in Figure 1 is the cumulative effect of the most important
risk factors, i.e., genotype, folate deficit and HDL choles-
terol deficit. An indiviual with CT genotype and deficient
folate and cHDL is almost 34 times more likely to suffer
from hyperhomocysteinaemia; and if that same individ-
ual has these deficits plus the TT genotype, the likelihood
of his/her having high serum homocysteine levels is then
87 times higher.
Discussion
This study suffers from the limitations inherent in all
cross-sectional studies, in that it does not allow for causal
or temporal relationships among variables to be estab-
lished, thus rendering it necessary for subsequent analyti-
cal epidemiological studies to be conducted in order to
confirm the results and hypotheses generated. Further-
more, some confounding variables may not have not been
included in this study, e.g., methionine intake, creatinine
levels, or polymorphisms of the nicotinamide-methyl-
transferase enzyme (chromosome 11q23), which have
recently been linked to plasma homocysteine levels [33].
Table 2: Threshold determination to define hyperhomocysteinemia
Hyperhomocysteinemia P50 P75 P90 P95 Hcy ≥ 12 Hcy ≥ 15
Threshold [Hcy]/μM 4.30 5.93 8.23 10.41 12.00 15.00
Number of cases 157 78 32 15 8 4
Prevalence % 49.53 24.61 10.1 4.73 2.52 1.26
95% CI 43.99-55.06 19.84-29.37 6.78-13.41 2.38-7.08 0.79-4.26 0.03-2.50
P: percentile
Table 3: Prevalence of cardiovascular risk factors and lipid profile
Total (%) Gender* Age* MTHFR C677T genotype*
Male Female 13 14 >14 CC CT TT
Overweight 30.3 35.9 25.6 ns ns
Hypertension 8.5 ns ns ns
Glucose (≥ 100 mg/dl) 15.3 22 9.6 ns ns
Total cholesterol (≥ 200 mg/dl) 7.0 2.8 10.5 ns ns
HDL cholesterol (≤ 35 mg/dl) 13.8 20.1 8.3 ns ns
LDL cholesterol (≥ 130 mg/dl) 6.4 ns ns ns
Total cholesterol/cHDL
(>5en /4.5 en )
9.1 ns ns ns
cLDL/cHDL
(>3.5 /3 )
8.5 ns ns ns
Smoking 7.6 ns 3.2 14.5 19.1 ns
Alcohol 9.8 ns 1.9 12.5 12.8 ns
Sedentariness 17.7 9 25.1 ns ns
Folate (≤ 5.3 nmol/l) 23.8 ns ns 18.8 20.4 46.7**
Vitamin B12
(≤ 336 pmol/l)
24.6 30.3 10 ns ns
*Statistically significant p < 0.05. ns: non-significant; ** differences in folate deficit were statistically significant (p < 0.001) only for homozygotic TT 
mutation. CT heterozygotic mutation does not show an statistically significant difference (p = 0.758)
HDL: High Density Lipoproteins
LDL: Low Density Lipoproteins
MTHFR: methylenetetrahydrofolate reductase
C: Cytosine; T:ThymineNutrition & Metabolism 2009, 6:39 http://www.nutritionandmetabolism.com/content/6/1/39
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In Spain, Gutiérrez-Revilla et al. (n = 83), Vilaseca et al. (n
= 195) and Mainou et al. (n = 80) have respectively pub-
lished cross-sectional studies in children and adolescents.
The first two targeted the population aged 0 to 18 years,
and the third the population aged 5 to 18 years. Ours is
the first study conducted in Spain and focused on the ado-
lescent population to have a substantial sample size.
In Western countries, vitamin deficiencies are rather infre-
quent, but in populations with important vitamin defi-
ciencies, plasma homocysteine levels rise until reaching
age-adjusted hyperhomocysteinaemia prevalences of 73%
in men and 41% in women, as shown by a recent study
conducted in Iran [34].
The distribution of the various polymorphisms of the
MTHFR C677T enzyme in our sample was very similar to
that observed in other studies [35,36], i.e., Hiraoka, with
32.9%, 51.6% and 15.5%, in CC, CT and TT respectively
[37], or Gutiérrez-Revilla et al., with 42.2%, 41% and
16.9%, in CC, CT and TT respectively [25]. The cardiovas-
cular risk factors studied showed no significant variation
according to MTHFR genotype, which only affects folate
and serum homocysteine levels.
The mean homocysteine values obtained by us are very
similar to those found in children and adolescents in Nor-
way and the USA, namely, 5.25 and 5 μmol/l, respectively
[38,39]. There is no international consensus regarding the
establishment of a cut-off point for defining hyperhomo-
cysteinaemia, and there are still fewer data relating to the
adolescent population. Prevalence of hyperhomocystein-
aemia in the study population was 1.26% for 15 μmol/L
and 2.52 for 12 μmol/L, results very similar to those
recently obtained in young adults aged 20-22 years in
Tokyo (1.18% for > 15 μmol/L) [37]. Taking into account
other international studies, which use percentiles for
determining other magnitudes in childhood and adoles-
cence, the 90th percentile is considered a good cut-off
point for defining hyperhomocysteinaemia in developed
countries [29,40,41]. In our study, this cut-off allowed us
to show a statistically significant increase of plasma
homocysteine levels depending on the study variables. In
line with other studies [5,23,42-46], prevalence of hyper-
homocysteinaemia was seen to increase in our study with
the MTHFR C677T mutant allele (2- and 6-fold for partial
and total C→T mutation, respectively), serum folate defi-
cit (5-fold) and cHDL deficit (2.7-fold). No significant
association was found with vitamin B12 after adjusting by
age, gender and CV risk factors.
It has been observed that the coexistence of several risk
factors, none of which is necessarily elevated to an extraor-
dinary degree, in any given individual can actually be
more dangerous than the existence of a single factor,
regardless of its magnitude [44,47]. In our study, as previ-
Table 4: Adjusted ORs for hyperhomocysteinemia
Odds Ratio 95% CI p
cHDL deficit*,** 2.786 1.089-7.126 0.033
Folate deficit*,*** 5.140 2.347-11.256 <0.001
MTHFR C677T genotype *
CT 2.362 1.107-5.042 0.001
TT 6.124 2.301-16.303
*Statistically significant.
HDL: High Density Lipoproteins
MTHFR: methylenetetrahydrofolate reductase
C: Cytosine; T:Thymine
**<5.3 nmol/l
***<35 mg/dl
Cumulative ORs: Folate, cHDL and MTHFR C677T genotype Figure 1
Cumulative ORs: Folate, cHDL and MTHFR C677T 
genotype. Cumulative effect of risk factors in homocystein 
prevalence. HDL: High Density Lipoproteins. MTHFR: meth-
ylenetetrahydrofolate reductase. C: Cytosine; T: Thymine; 
CC: normal genotype; CT: partial mutation; TT: mutation in 
homozygosis.
Folate deficit
(<5.3 nmol/l)
OR = 5.140
cHDL deficit
(<35 mg/dl
OR = 2.786
OR= 
14.32
OR= 
17.06
OR= 
87.70
OR= 
31.48
Genotipe
CCCT
OR = 2.362Nutrition & Metabolism 2009, 6:39 http://www.nutritionandmetabolism.com/content/6/1/39
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ously described in Guo et al [48], prevalence of hyperho-
mocysteinaemia increases when risk factors accumulate.
The probability of being hyperhomocysteinemic is 5
times higher with deficit serum folate levels than it is with
normal values. If, the person concerned also happens to
be a carrier of the MTHFR TT polymorphism, this risk is
then multiplied by 30 because his/her ability to metabo-
lise homocysteine is very reduced; and if, in addition to
this, such a person has HDL cholesterol levels below 35
mg/dl, the likelihood of his/her being hyperhomo-
cysteinemic is multiplied by 90. These results suggest that
the higher decile is an appropriate cut-off to define homo-
cysteinemia in adolescents.
While many national and international studies link deficit
serum folate levels to hyperhomocysteinaemia and sug-
gest dietary supplementation as a preventive strategy for
reducing cardiovascular risk [48-53], other authors con-
tend that, as hyperhomocysteinaemia has not yet been
shown to be an independent risk factor, dietary supple-
mentation is not justified [54].
We thus feel that we are confronted by a still unresolved
research question, and trust that our study may serve as a
further contribution towards finding an answer in this
field of investigation
Conclusion
A good definition of hyperhomocysteinaemia in adoles-
cents is the 90th percentile, equivalent to 8.23 μmol/L.
Risk factors for hyperhomocysteinaemia are cHDL and
folate deficiency, and the MTHFR C677T mutant geno-
type. Coexistence of all three factors increases the risk of
suffering from hyperhomocysteinaemia 87-fold.
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